Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Advanced Parkinson's Disease (PRESTO Extension)
NCT00203177Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2001
- Primary completion
- Dec 2006
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of rasagiline in Parkinson's disease (PD) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Long-term safety and tolerability of rasagiline at 6 months. Started Oct 2001; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00203177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203177.